<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Omeprazole</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00338</strong>&#160; (APRD00446)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00338/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00338/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00338.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00338.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00338.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00338.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00338.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00338">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>OMEP</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>OMP</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>OMZ</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Omeprazole magnesium </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000131/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000131/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: KWORUUGOSLYAGD-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 712.198816192</li>
              <li>Average Mass: 713.121</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000131">DBSALT000131</a></td>
      </tr>
      <tr>
        <td>
          <strong>Omeprazole sodium</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000857/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000857/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000857">DBSALT000857</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Antra</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Audazol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Belmazol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ceprandal</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Danlox</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Desec</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Elgam</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Emeproton</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Gasec</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Gastrimut</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Gastroloc</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Indurgan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Inhibitron</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Logastric</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Losec</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mepral</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mopral</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Olexin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Omapren</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Omepral</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Omeprazon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Omeprol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Omezol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Omisec</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Omizac</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ortanol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Parizac</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Prazidec</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Prazolit</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Prilosec</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Procelac</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ramezol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Regulacid</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Sanamidol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ulceral</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ulcesep</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ultop</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zegerid</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zepral</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/enzyme-inhibitors">Enzyme Inhibitors</a></li>
<li><a href="/mesh/anti-ulcer-agents">Anti-Ulcer Agents</a></li>
<li><a href="/mesh/proton-pump-inhibitors">Proton Pump Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>73590-58-6</td></tr><tr><th>Weight</th><td>Average: 345.416<br>Monoisotopic: 345.114712179</td></tr><tr><th>Chemical Formula</th><td>C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>S</td></tr><tr><th>InChI Key</th><td>SUBDBMMJDZJVOS-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">6-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl}-1H-1,3-benzodiazole</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzimidazoles</td></tr><tr><th>Subclass</th><td>Sulfinylbenzimidazoles</td></tr><tr><th>Direct parent</th><td>Sulfinylbenzimidazoles</td></tr><tr><th>Alternative parents</th><td>Anisoles; Alkyl Aryl Ethers; Pyridines and Derivatives; Imidazoles; Sulfoxides; Polyamines</td></tr><tr><th>Substituents</th><td>phenol ether; anisole; alkyl aryl ether; pyridine; benzene; imidazole; azole; sulfoxide; ether; polyamine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Omeprazole is indicated for the treatment of duodenal ulcers, benign gastric ulcers, gastroesophageal reflux disease (GERD), heartburn and other symptoms associated with GERD, erosive esophagitis, and long-term treatment of pathological hypersecretory conditions like Zollinger-Ellison syndrome, multiple endocrine adenomas, and systemic mastocytosis. </td></tr><tr><th>Pharmacodynamics</th><td>After oral administration, the onset of the anti-secretory effect of omeprazole occurs within one hour and maximum effect occurring within two hours. At 24 hours, inhibition of secretion is approximately 50% of maximum and duration of inhibition lasts up to 72 hours. Although omeprazole has a very short plasma half-life, the anti-secretory effect lasts for a long time due to prolonged binding to parietal H+/K+ ATPase enzyme. When the drug has been discontinued, secretory activity will return to baseline over 3-5 days. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days. In studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion. Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date. </td></tr><tr><th>Mechanism of action</th><td>Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup>-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity.</td></tr><tr><th>Absorption</th><td>The delayed-release capsule are enteric-coated (as omeprazole is acid-labile) so the absorption of omprazole begins once the granules leave the stomach. Absorption is rapid. Peak plasma levels occur within 0.5 - 3.5 hours. The absolute bioavailability (compared with intravenous administration) of the delayed-release capsule is 30-40% at doses of 20 - 40 mg, due to presystemic metabolism. This value increases slightly when given repeatedly. Based on a relative bioavailability study, the AUC and Cmax of PRILOSEC (omeprazole magnesium) for Delayed-Release Oral Suspension were 87% and 88% of those for PRILOSEC Delayed-Release Capsules, respectively. Interestingly, when the 40 mg delayed release capsule is given with or without applesauce, it is bioequivalent. However, when the 20 mg delayed release capsule is given with the same conditions, it is not bioequivalent. When the same capsule is given to the elderly, bioavailability increases. Omeprazole was 76% bioavailable. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>95% bound to human plasma protein. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Omeprazole is extensively metabolized by the cytochrome P450 (CYP) enzyme system. The two primary CYP isozymes involved are CYP2C19 and CYP3A4. Metabolism is stereoselective in which the S-isomer is converted to 5'O-desmethylomeprazole via CYP2C19. CYP3A4 converts the S-isomer to 3-hydroxyomeprazole. The R-isomer is converted to 5-hydroxyomeprazole by CYP2C19. CYP3A4 converts the R-isomer to any four different metabolites: 5-hydroxyomeprazole (5-OH OME), omeprazole sulfone (OME sulfone), 5'-O-desmethylomeprazole (5'-desmethyl OME), and 3-hydroxyomeprazole (3-OH OME). </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Omeprazole</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00185">5-Hydroxyomeprazole</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/186">Details</a></td></tr><tr><td>Omeprazole</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00186">5'-O-Desmethyl omeprazole</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/187">Details</a></td></tr><tr><td>Omeprazole</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00187">Omeprazole sulfone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/188">Details</a></td></tr><tr><td>Omeprazole</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00188">3-Hydroxyomeprazole</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/189">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Urinary excretion is a primary route of excretion of omeprazole metabolites. Little, if any unchanged drug was excreted in the urine. The majority of the dose (about 77%) was eliminated in urine as at least six metabolites. Two were identified as hydroxyomeprazole and the corresponding carboxylic acid. The remainder of the dose was recovered in the feces. </td></tr><tr><th>Half life</th><td>0.5-1 hour (healthy subjects, delayed-release capsule); 
3 hours (hepatic impairment) </td></tr><tr><th>Clearance</th><td><ul>
	<li>500 &#8211; 600 mL/min [Total body clearance, healthy subjects, delayed-release capsule]</li>
	<li>250 mL/min [Plasma clearance, Geriatric]</li>
	<li>70 mL/min [Plasma clearance, Hepatic Impairment]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Cytochrome P450 2C19<br>Gene symbol: CYP2C19<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P33261" target="_blank">P33261 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs4244285" target="_blank">rs4244285 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2C19*2</td><td>A Allele, homozygote</td><td>Poor metabolizer, lower dose requirement, improved drug efficacy</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/9867757" target="_blank" title="Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998 Dec 15;129(12):1027-30.">9867757 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Cytochrome P450 2C19<br>Gene symbol: CYP2C19<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P33261" target="_blank">P33261 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs4986893" target="_blank">rs4986893 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2C19*3</td><td>A Allele, homozygote</td><td>Poor metabolizer, lower dose requirement, improved drug efficacy</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/9867757" target="_blank" title="Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998 Dec 15;129(12):1027-30.">9867757 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9968</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.6326</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5573</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.6622</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.968</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.542</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7838</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.6175</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6901</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.7505</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.796</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.7895</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5692
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8318
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9778
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2254 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.719
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8977
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Apotex inc</li>
<li>Dr reddys laboratories ltd</li>
<li>Impax laboratories inc</li>
<li>Kremers urban development co</li>
<li>Lek pharmaceuticals d d</li>
<li>Mylan pharmaceuticals inc</li>
<li>Sandoz inc</li>
<li>Watson laboratories inc florida</li>
<li>Astrazeneca lp</li>
<li>Dexcel pharma technologies ltd</li>
<li>Santarus, Inc.</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.aidarex.com">Aidarex Pharmacuticals LLC</a></li>
<li><a href="http://www.alturapharma.com">Altura Pharmaceuticals Inc.</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Astra Pharma Inc.</li>
<li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.bpipack.com">Blenheim Pharmacal</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li><a href="http://www.stirol.net">Concern Stirol</a></li>
<li><a href="http://www.cprwebsite.com">Contract Packaging Resources Inc.</a></li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li>Coupler Enterprises Inc.</li>
<li><a href="http://www.cvs.com">CVS Pharmacy</a></li>
<li>Dept Health Central Pharmacy</li>
<li><a href="http://www.dexcel.com">Dexcel Ltd.</a></li>
<li>DHHS Program Support Center Supply Service Center</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li>Ftl International Inc.</li>
<li><a href="http://www.globalphar.com">Global Pharmaceuticals</a></li>
<li><a href="http://www.gsms.us">Golden State Medical Supply Inc.</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.impaxlabs.com">Impax Laboratories Inc.</a></li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.keltman.com">Keltman Pharmaceuticals Inc.</a></li>
<li><a href="http://www.esteve.es">Laboratorios Dr Esteve SA</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.lek.si">Lek Pharmaceuticals Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.medsource-direct.com">Medsource Pharmaceuticals</a></li>
<li><a href="http://www.merck.com">Merck &amp; Co.</a></li>
<li><a href="http://www.merial.com">Merial Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.perrigo.com">Perrigo Co.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li><a href="http://www.pg.com">Procter &amp; Gamble</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>S&amp;P Healthcare</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.santarus.com">Santarus Inc.</a></li>
<li>Schwarz Pharma Inc.</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li>St Mary's Medical Park Pharmacy</li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Torpharm Inc.</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule, delayed release</td><td>Oral</td><td>10 mg, 20 mg, 40 mg</td></tr><tr><td>Suspension</td><td>Oral</td><td>2 mg/mL</td></tr><tr><td>Tablet, delayed release</td><td>Oral</td><td>20 mg </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/1795">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1735">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>Omeprazole may increase the effect of the benzodiazepine, alprazolam.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB06237">Avanafil</a></td><td>Nineteen healthy male volunteers received a single 40 omeprazole delayed-release capsule once daily for 8 days (Days 1-8), and a single 200 mg avanafil on Day 8. Twelve hour pharmacokinetics of omeprazole on Days 7 and 8 were compared. Co-administration with avanafil resulted in an approximate 5.9% increase in AUC0-inf and 8.6% increase in Cmax of omeprazole. </td></tr><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>Affects hepatic CYP1A2 metabolism, thus increasing bendamustine levels. Concentration of active metabolites may be decreased due to decreased conversion. </td></tr><tr><td><a href="/drugs/DB01066">Cefditoren</a></td><td>Proton pump inhibitors such as omeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.</td></tr><tr><td><a href="/drugs/DB00475">Chlordiazepoxide</a></td><td>Omeprazole may increase the effect of the benzodiazepine, chlordiazepoxide.</td></tr><tr><td><a href="/drugs/DB01166">Cilostazol</a></td><td>Omeprazole increases the effect of cilostazol</td></tr><tr><td><a href="/drugs/DB01068">Clonazepam</a></td><td>Omeprazole may increase the effect of the benzodiazepine, clonazepam.</td></tr><tr><td><a href="/drugs/DB00758">Clopidogrel</a></td><td>Omeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Clopidogrel prescribing information recommends avoiding concurrent use with omeprazole, due to the possibility that combined use may result in decreased clopidogrel effectiveness. </td></tr><tr><td><a href="/drugs/DB00628">Clorazepate</a></td><td>Omeprazole may increase the effect of the benzodiazepine, clorazepate.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Omeprazole increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB01254">Dasatinib</a></td><td>Omeprazole may decrease the serum level of dasatinib.</td></tr><tr><td><a href="/drugs/DB00829">Diazepam</a></td><td>Omeprazole may increase the effect of the benzodiazepine, diazepam.</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>The beta-blocker increases toxicity of disopyramide</td></tr><tr><td><a href="/drugs/DB00467">Enoxacin</a></td><td>Omeprazole may decrease the absorption of enoxacin.</td></tr><tr><td><a href="/drugs/DB01215">Estazolam</a></td><td>Omeprazole may increase the effect of the benzodiazepine, estazolam.</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Omeprazole increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00690">Flurazepam</a></td><td>Omeprazole may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Omeprazole increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00801">Halazepam</a></td><td>Omeprazole may increase the effect of the benzodiazepine, halazepam.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Omeprazole decreases the absorption of indinavir</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>The proton pump inhibitor, omeprazole, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB01587">Ketazolam</a></td><td>Omeprazole may increase the effect of the benzodiazepine, ketazolam.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>The proton pump inhibitor, omeprazole, may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Omeprazole increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>Omeprazole increases the levels of methotrexate</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Omeprazole may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB04938">Ospemifene</a></td><td>Moderate CYP2C19 inhibitors may increase levels of ospemifene. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Omeprazole increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB01588">Prazepam</a></td><td>Omeprazole may increase the effect of the benzodiazepine, prazepam.</td></tr><tr><td><a href="/drugs/DB01589">Quazepam</a></td><td>Omeprazole may increase the effect of the benzodiazepine, quazepam.</td></tr><tr><td><a href="/drugs/DB08864">Rilpivirine</a></td><td>Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. </td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Affects CYP1A2 metabolism; decreases level or effect of roflumilast. </td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort decreases the levels/effects of omeprazole </td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Omeprazole may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Omeprazole therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Omeprazole. Consider alternate therapy or increase the dose of Omeprazole based on the therapeutic response. </td></tr><tr><td><a href="/drugs/DB06273">Tocilizumab</a></td><td>Omeprazole is a CYP2C19 and CYP3A4 substrate. Exposure of omeprazole decreases following administration of tocilizumab.. </td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>Omeprazole may increase the effect of the benzodiazepine, triazolam.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The strong CYP2C19 inhibitor, Omeprazole, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Omeprazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB08828">Vismodegib</a></td><td>Vismodegib serum concentrations may be decreased by proton pump inhibitors such as omeprazole.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole increases the effect and toxicity of omeprazole</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take 30-60 minutes before meals.</li></ul></td></tr></tbody></table>